Why Some People Recover Faster From Pain
- Leon Wirz
- 5 days ago
- 6 min read
Published in Science Immunology, February 2026 | Michigan State University & University of North Carolina
Introduction
Chronic pain is one of the most underestimated public health challenges worldwide. In the United States alone, more than 100 million people are affected. In Europe and Switzerland, musculoskeletal pain and post-traumatic pain are among the leading causes of disability, reduced productivity, and long-term insurance claims.
One consistent observation across epidemiological studies is that women are more likely than men to develop chronic pain. They often experience longer-lasting pain after injury or inflammation. Until recently, this was largely described as a clinical fact without a clear biological explanation.
A new study published in Science Immunology now provides a mechanistic answer. The researchers identify a specific immune cell population (IL-10–producing monocytes) that actively drives pain resolution. Importantly, this mechanism operates more efficiently in males due to androgen (male sex hormone) signaling.
This shifts the narrative: pain resolution is not passive recovery. It is an active biological program regulated by the immune system.
The Core Discovery
The study centers around interleukin-10 (IL-10), a cytokine (a signaling protein used by immune cells to communicate). IL-10 is traditionally described as anti-inflammatory because it suppresses pro-inflammatory cytokines such as TNF-α and IL-1β. However, this study shows that IL-10 does more than dampen inflammation. It directly acts on sensory neurons (pain-detecting nerve cells) to reduce their excitability.
In inflamed skin tissue, specific immune cells called monocytes (a type of circulating white blood cell that can enter tissues during inflammation) infiltrate the site of injury. A subset of these monocytes produces IL-10. The released IL-10 binds to IL-10 receptor 1 (IL-10R1) expressed on nociceptive neurons (pain-sensing neurons). This signaling reduces neuronal hyperexcitability (abnormally increased firing of pain neurons), thereby promoting pain resolution.
The key finding is that male mice accumulate significantly more IL-10–producing monocytes in inflamed tissue than females. As a result, males resolve inflammatory pain faster. When IL-10 is removed from monocytes, or when its receptor is deleted from sensory neurons, pain resolution is delayed in both sexes.
In humans, the pattern is similar: after traumatic injury, men showed higher circulating IL-10 levels and a faster reduction in pain over three months compared with women. Higher IL-10 levels were statistically associated with better recovery.
How the Study Was Conducted
The researchers used a multi-layered experimental approach combining mouse models and human longitudinal data.
In the preclinical model, inflammatory pain was induced in mice by injecting complete Freund’s adjuvant (CFA) (a compound that provokes strong localized immune activation). Both male and female mice developed comparable levels of inflammation and similar initial pain sensitivity. Importantly, the degree of tissue swelling (edema) did not differ between sexes. The difference emerged during the recovery phase: male mice began resolving pain after approximately one week, whereas females remained hypersensitive for 5-10 additional days.
To identify the cellular source of IL-10, the team used IL-10 reporter mice in which IL-10–producing cells fluoresce. They observed that IL-10 was predominantly produced by infiltrating monocytes in the inflamed skin. Males had a higher number of these IL-10–positive monocytes. Moreover, the number of IL-10–producing monocytes correlated directly with faster normalization of pain thresholds.
To test causality, several genetic and pharmacological manipulations were performed. Deleting IL-10 specifically from myeloid cells (a lineage that includes monocytes) prolonged pain. Removing IL-10 receptors from sensory neurons produced a similar delay. Conversely, injecting recombinant IL-10 directly into inflamed tissue accelerated pain resolution in both sexes. This demonstrates that IL-10 signaling in neurons is functionally relevant and not merely correlated.
The role of sex hormones was then examined. Removing ovaries in female mice did not significantly alter pain duration. However, supplementing females with dihydrotestosterone (DHT, a potent androgen) increased IL-10–producing monocytes and accelerated pain resolution to a male-like pattern. In contrast, orchiectomy (removal of testes) in males reduced IL-10 production and delayed recovery. Blocking androgen receptors pharmacologically or deleting androgen receptors specifically in monocytes impaired IL-10 production and slowed resolution.
These experiments establish that androgen receptor signaling in monocytes enhances IL-10 production, explaining the sex difference.
Finally, the researchers evaluated Resolvin D1 (RvD1), a specialized pro-resolving lipid mediator (a molecule derived from omega-3 fatty acids that actively promotes resolution of inflammation). A single local injection of RvD1 increased IL-10–producing monocytes and accelerated pain resolution in both sexes. Notably, this effect disappeared in mice lacking IL-10 in monocytes, indicating that RvD1 acts through this pathway.
The translational arm of the study used data from the AURORA cohort, a longitudinal study of trauma survivors. Pain severity was assessed immediately after injury and at follow-up intervals up to 84 days. Acute pain levels were similar in men and women. Over time, men exhibited faster pain reduction. Blood analysis revealed higher IL-10 levels and higher estimated monocyte proportions in men. Statistical mediation modeling suggested that IL-10 partially mediates the relationship between monocyte levels and pain recovery.
Key Findings
The study demonstrates that pain resolution requires active communication between immune cells and sensory neurons. IL-10 produced by monocytes directly reduces neuronal excitability. Males show higher IL-10–producing monocyte numbers due to androgen signaling. Enhancing this pathway pharmacologically can accelerate recovery. Human data align with the preclinical findings, suggesting biological relevance across species.
Limitations of the Study
Although the findings are robust, several limitations must be considered. The mouse model used localized inflammatory pain, whereas human trauma involves heterogeneous injuries and systemic immune responses. In mice, IL-10 production was measured directly in inflamed skin. In humans, cytokines were measured in blood, and immune cell proportions were estimated using CIBERSORT (a computational method that infers immune cell composition from bulk RNA sequencing data rather than direct single-cell measurement). Therefore, the human findings are correlational.
Moreover, systemic IL-10 modulation was not tested clinically, and long-term hormonal manipulation carries its own risks. Differences in anatomy between species (for example, direct access of circulating cytokines to dorsal root ganglia (clusters of sensory neuron cell bodies)) in humans may influence neuroimmune communication.
Nevertheless, the consistency between mechanistic mouse data and longitudinal human observations strengthens the translational relevance.
Relevance for Switzerland
For Switzerland, where chronic musculoskeletal pain represents a major driver of disability insurance costs and lost productivity, these findings are highly relevant. Women show higher chronic pain prevalence and often longer rehabilitation durations. Understanding that biological resolution mechanisms differ by sex suggests that personalized pain management strategies may be necessary.
From a health economics perspective, accelerating pain resolution even modestly could reduce long-term disability claims, decrease opioid prescriptions, and shorten physiotherapy or rehabilitation timelines. Swiss insurers and policymakers increasingly emphasize preventive medicine. Immune profiling after trauma or surgery could identify high-risk individuals and guide early intervention.
For the Swiss biotech and pharma ecosystem, which is strong in immunology and inflammation research, targeting pro-resolving pathways such as IL-10 or resolvin-based therapies represents a promising translational opportunity.
Potential Impacts of a Successful Therapy
If therapies that safely enhance IL-10–producing monocytes become clinically viable, they could reduce the transition from acute to chronic pain. This would have implications not only for trauma patients but also for postoperative recovery and inflammatory diseases. Personalized approaches could account for immune phenotype and sex-specific biology rather than applying uniform analgesic protocols.
Such strategies might also reduce reliance on opioids, an important public health goal globally.
Risks
However, IL-10 is an immunosuppressive cytokine. Excessive systemic activation could increase infection risk or impair tumor immune surveillance. Hormonal modulation carries cardiovascular and endocrine risks. Therefore, targeted local therapies or pro-resolving mediators such as RvD1 may represent safer avenues than systemic cytokine administration.
Overall Assessment
This study provides a compelling mechanistic explanation for sex differences in pain duration. It moves beyond descriptive epidemiology and identifies a concrete immune-neuronal pathway. By demonstrating that pain resolution is an active biological process driven by monocyte-derived IL-10 and regulated by androgen signaling, the research opens new avenues for precision pain medicine.
While clinical translation will require careful safety evaluation and human intervention trials, the conceptual advance is substantial. Pain persistence may not solely reflect injury severity but also insufficient activation of resolution pathways.
What Comes Next
Future research will likely focus on validating IL-10–based biomarkers in clinical cohorts, testing pro-resolving mediators in controlled trials, and exploring whether chronic pain patients exhibit impaired IL-10–producing monocyte responses. Understanding whether this pathway operates similarly in autoimmune pain conditions, neuropathic pain, or postoperative settings will be crucial.
If confirmed, this mechanism could reshape how we think about preventing chronic pain, particularly in populations at higher risk.
Reference
Jaewon Sim et al.,
Monocyte-derived IL-10 drives sex differences in pain duration.
Sci. Immunol.11,eadx0292(2026).
Comments